NCT04591431 The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04588545 Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04538742 A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04514419 Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04419181 Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer Status WITHDRAWN Phase PHASE2
NCT04398914 Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04337658 Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer Status NOT_YET_RECRUITING Phase PHASE3
NCT04329065 Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer Status RECRUITING Phase PHASE2
NCT04266249 CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04253561 Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients Status COMPLETED Phase PHASE1
NCT04208178 Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04197687 TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Status UNKNOWN Phase PHASE2
NCT04193059 Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04188548 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04172259 ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04158258 A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America Status COMPLETED Phase N/A
NCT04108858 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT03988036 A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) Status COMPLETED Phase PHASE2